Metabolic dysfunction-associated steatotic (fatty) liver disease (MASLD), previously termed
non-alcoholic fatty liver disease, is a worldwide epidemic that can lead to hepatic …

Background Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been
increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD …

Introduction There are no drugs approved by regulatory agencies for the treatment of
nonalcoholic fatty liver disease (NAFLD); incretin combination therapies are being …

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting liver disease that affects
millions of people around the world. It is best identified with a hepatic fat build-up that …

Glycaemic control is the basis of type 2 diabetes mellitus (T2DM) management and is crucial
for preventing diabetes microvascular and macrovascular complications. The South Asian …

Background Previously, we found low-carbohydrate diets slowed prostate cancer (PC)
growth and increased survival vs. a Western diet in mice, by inhibiting the insulin/IGF-1 axis …

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease
worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus …

The bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease)
NAFLD is indicated by the higher prevalence and worse disease course of one condition in …

Metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes (T2D) are
interconnected metabolic disorders with significant health implications. However, a …

Hepatic steatosis and its main cause—nonalcoholic fatty liver disease (NAFLD) is the most
common hepatic abnormality, affecting about 30% of adult population [1]. NAFLD is …